Grifols (NASDAQ:GRFS) Shares Gap Up – Should You Buy?

Grifols, S.A. (NASDAQ:GRFS)’s share price gapped up before the market opened on Tuesday . The stock had previously closed at $8.34, but opened at $8.73. Grifols shares last traded at $8.67, with a volume of 139,494 shares changing hands.

Grifols Stock Up 7.0 %

The company has a market cap of $6.03 billion, a price-to-earnings ratio of 8.68 and a beta of 0.50. The stock has a 50-day simple moving average of $8.82 and a 200-day simple moving average of $7.77. The company has a current ratio of 1.68, a quick ratio of 0.80 and a debt-to-equity ratio of 1.06.

Grifols (NASDAQ:GRFS) last announced its earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.21). The company had revenue of $1.96 billion for the quarter. As a group, analysts predict that Grifols, S.A. will post 0.79 EPS for the current year.

Institutional Trading of Grifols

Institutional investors have recently modified their holdings of the company. GAMMA Investing LLC boosted its holdings in Grifols by 49.4% during the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock worth $30,000 after buying an additional 1,135 shares in the last quarter. Signaturefd LLC lifted its position in shares of Grifols by 66.2% during the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 2,153 shares during the last quarter. AQR Capital Management LLC bought a new stake in shares of Grifols during the 2nd quarter worth $89,000. Creative Planning grew its holdings in shares of Grifols by 26.4% in the 3rd quarter. Creative Planning now owns 17,319 shares of the biotechnology company’s stock worth $154,000 after acquiring an additional 3,614 shares during the last quarter. Finally, International Assets Investment Management LLC acquired a new stake in shares of Grifols during the third quarter worth $1,700,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.